A thalidomide analog, (4‐(1,3‐dioxo‐1,3‐dihydro‐2H‐isoindol‐2‐yl)‐N′‐[(4‐ethoxyphenyl)
methylidene] benzohydrazide), has been identified as a promising broad‐spectrum anti‐inflammatory
agent in previous study. In this study, a sensitive and selective UPLC‐MS/MS assay
was developed and validated for its determination in rat plasma samples. The chromatographic
separation was performed on an Aquity BEH C18 column using mobile phase comprising
of acetonitrile and 10mM ammonium acetate in the ratio of 85: 15, at flow rate of 0.3 mL/min.